اللحين اهيه باللو السنويSalix Pharmaceuticals Ltd. SLXP

[hassn]

اشرايكم بهالشركه شركه صيدله (SLXP)

اللحين اهيه باللو السنوي الرجاء من المحللين تحليل هالسهم على العلم ان سعره اليوم 7.88 والهاي السنوي 16.38


وهذا من اخبار الشركه الرجاء التحليل وشكرا

bizjournals.com
Generic competition pummels Salix shares
Monday December 31, 4:35 pm ET


Shares of Salix Pharmaceuticals tumbled Monday as news of generic competition for the company's top-selling drug overshadowed the filing of a New Drug Application for a different product.
Raleigh-based Salix (Nasdaq: SLXP - News) announced Friday that it is partnering with Watson Pharmaceuticals to create a generic version of Colazal, an anti-inflammatory drug that accounted for almost half of Salix's $67.4 million in product revenue in the third quarter. Salix made the move in reaction to the Food and Drug Administration approving genetic versions of Colazal from drugmakers Apotex and Roxanne. Mylan Inc. of Pittsburgh announced Monday that it also has received FDA approval for a generic Colazal.

ADVERTISEMENT


The rush of generic Colazals hitting the market prompted Piper Jaffray to downgrade its rating on Salix shares from "hold" to "sell." Traders responded by dropping Salix shares 12.54 percent, to $7.88, at the close of markets Monday.

Also Monday, Salix said it has filed an NDA for its granulated mesalamine treatment for ulcerative colitis, a long-term condition in which ulcers line the rectum and colon, causing bleeding and diarrhea. Salix said it expects the FDA review of granulated mesalamine to last 10 months. Salix licensed rights to the treatment from Germany's Dr. Falk Pharma, which sells the drug in Europe.

Published December 31, 2007 by the Triangle Business Journal

 

[hassn]

وخبر يديد وارتفاع 8.17


Form 8-K for SALIX PHARMACEUTICALS LTD


--------------------------------------------------------------------------------

2-Jan-2008

Entry into a Material Definitive Agreement, Financial Statements and Ex



Item 1.01. Entry into a Material Definitive Agreement.
On December 28, 2007, Salix Pharmaceuticals, Ltd. announced that it had entered into a Supply and Distribution Agreement with Watson Pharma, Inc., pursuant to which Watson will be Salix's exclusive distributor to market and sell an authorized generic of Colazal® (balsalazide disodium) Capsules 750 mg, Salix's anti-inflammatory drug approved for the treatment of mildly to moderately active ulcerative colitis, in the United States. Watson agrees to use commercially reasonable efforts to sell authorized generic Colazal, and has sole discretion to establish prices and terms therefor. Watson will pay Salix a portion of its profits for sales under the agreement, and Salix will supply Watson with all its requirements for the product. The term of the agreement is five years from the December 28, 2007 launch date, provided that either party may terminate immediately upon bankruptcy of the other, or for uncured breaches of the other party. Salix may also terminate on 30 days notice if the agreement has become commercially unviable, if it obtains the right to prohibit other generics from being sold or if it ceases distribution of branded Colazal.

A copy of the press release announcing the agreement is attached to this current report on Form 8-K as exhibit 99.1. A copy of the agreement will be filed as an exhibit to Salix's Annual Report on Form 10-K for the fiscal year ending December 31, 2007.





Item 9.01. Financial Statements and Exhibits.
(d) Exhibits


Exhibit No. Description
99.1 Press release dated December 28, 2007 announcing the Supply and
Distribution Agreement between Salix Pharmaceuticals, Ltd. and
Watson Pharma, Inc.

 

[hassn]

نبي راي المحللين